Gilgamesh Pharmaceuticals
Focus on early clinical development and experimental medicine and translational neuroscience approaches. Successfully led the early clinical development of compounds in schizophrenia, autism, and major depression. He is currently the head of the psychiatry/neurodevelopmental group in translational medicine neuroscience at Roche.
This person is not in any offices
Gilgamesh Pharmaceuticals
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy.